Moreover, clinical findings suggest that malignant tumors appropriate for mTOR inhibitors may include those that are highly addicted to angiogenesis (such as renal cell carcinoma, neuroendocrine tumors and possibly hepatocellular carcinoma) or to cyclin D1 overexpression (such as mantle cell lymphoma). The gene discussed is MTOR; the disease is cancer.